Combination therapy with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus

Archives of Internal Medicine

Volumn 163, Issue 9, 2003, Pages 1025-1029

  Rosner, Mitchell H ^a,b   Okusa, Mark D ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Medical Associates of Savannah   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL;

BLOOD PRESSURE REGULATION; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME INHIBITION; HEART PROTECTION; HUMAN; KIDNEY FUNCTION; LIFE EVENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HUMANS; RECEPTORS, ANGIOTENSIN;

EID: 0037992870     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.9.1025     Document Type: Review

References (30)

1. United States Renal Data System. Excerpts from the United States Renal Data System 2001 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kid Dis. 2001;38 (suppl 3):S7-S195.
2. Parving H-H, Lenhert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
3. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
4. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
5. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care. 2002;25 (suppl 1):S1-S147.
6. Gerstein HC, Yusuf S, Mann JFE, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of the angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456- 1462.
8. Chaturvedi N, Stevenson J, Fuller JH, Rottiers R, Ferriss B, for the EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminemia or microalbuminemia. Lancet. 1997;349:1787-1792.
9. Parving H-H, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 2001;60:228-234.
10. Ruggenenti P, Perna A, Mosconi L, et al, for the GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349:1857-1863.
11. The Heart Outcomes Prevention Evaluation Study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
12. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1998;128:982-988.
13. Cooper ME. Renal protection and angiotensinconverting enzyme inhibition in microalbuminuric type I and type II diabetic patients. J Hypertens Suppl. 1996;14(suppl 6):S11-S14.
14. Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ. Incidence of macrovascular disease in diabetes mellitus: the London follow-up to the WHO multinational study of vascular disease in diabetics. Diabetologia. 1991;34:584-589.
15. Laasko M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-942.
16. Wingard DL, Barrett-Connor E. Heart disease and diabetes. In: Harris MI, Cowie CC, Stern MS, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. 2nd ed. Washington, DC: National Institutes of Health; 1995:429-448.
17. McLeod JM, Lutale J, Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia. 1995;38:610-616.
18. Neil A, Thorogood M, Hawkins M, Cohen D, Potok M, Mann J. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care. 1993;16:996- 1003.
19. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet. 1999;353:611-616.
20. Tatti P, Pahor M, Byington RB, et al. Outcome results of the fosinopril versus amiodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597-603.
21. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
22. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-720.
23. Lindholm LH, Ibsen H, Dahlof B, et al, for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004-1010.
24. Pitt B, Poole-Wilson PA, Segal R, et al, on behalf of the Elite II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trialthe Losartan Heart Failure Survival Study (ELITE II). Lancet. 2000;355:1582-1587.
25. Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
26. Peterson JC, Sharon A, Burkhart JM, for the Modification of Diet in Renal Disease (MDRD) Study Group. Blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med. 1995;123:754-762.
27. Nussberger J, Waeber B, Brunner HR. Clinical pharmacology of ACE inhibition. Cardiology. 1989;76 (suppl 2):11-22.
28. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637-645.
29. Kuriyama S, Tomonari H, Tokudome G, et al. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res. 2002;25:849-855.
30. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomized controlled trial. Lancet. 2003;361:117-124.